Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
2 Under-the-Radar Growth Stocks to Consider
10:15am, Wednesday, 10'th Apr 2024
Madrigal Pharmaceuticals recently earned a groundbreaking therapy approval. Axsome Therapeutics is getting closer to transforming its lineup of medicines.
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
07:00am, Wednesday, 10'th Apr 2024
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
11:26am, Tuesday, 02'nd Apr 2024
Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
07:00am, Monday, 01'st Apr 2024
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
07:44am, Wednesday, 27'th Mar 2024
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as di
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
12:26pm, Tuesday, 26'th Mar 2024
Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.
77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by t
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial
06:55am, Monday, 25'th Mar 2024
Axsome Therapeutics said on Monday its therapy for a sleep disorder met the main goal of a late-stage study.
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
06:45am, Saturday, 23'rd Mar 2024
Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
12:36pm, Thursday, 21'st Mar 2024
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
01:16pm, Wednesday, 20'th Mar 2024
Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
07:00am, Tuesday, 05'th Mar 2024
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
07:00am, Tuesday, 27'th Feb 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system
3 Biotech Stocks to Buy and Hold for the Next 10 Years
08:50am, Monday, 26'th Feb 2024
CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
11:41am, Wednesday, 21'st Feb 2024
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
